Beta-Blocker Evaluation in Survival Trial (BEST-BioLINCC)

**<u>Data Access NOTE:</u> **Please refer to the &#8220;Authorized Access&#8221; section below for information about how access to the data from this accession differs from many other dbGaP accessions. <u>Objectives </u><br>The Beta-Blocker Evaluation of Survival Trial was designed to determine whether bucindolol hydrochloride- a nonselective beta-adrenergic blocker and mild vasodilator- would reduce the rate of death from any cause among patients with advanced heart failure and to assess its effects in various subgroups defined by ethnic background and demographic criteria- specifically women and members of minority groups. <u>Background </u><br>Although beta-adrenergic-receptor antagonists reduce morbidity and Mortality in participants with mild-to-moderate chronic heart failure, their effort on survival in participants with more advanced heart failure is unknown. <u>Participants </u><br>There were 2,708 participants. <u>Conclusions </u><br>Bucindolol resulted in no significant overall survival benefit. (Krause-Steinrauf et al., 2001, PMID: [11386264](https://pubmed.ncbi.nlm.nih.gov/11386264/)).